Residual DNA Testing Market Size to Reach USD 519.69 Million by 2034 at a 5.9% CAGR from 2026 to 2034

The residual DNA testing market size was valued at USD 312.62 million in 2025 and is expected to reach USD 519.69 Million by 2034, growing at a CAGR of 5.9%. Residual DNA analysis comprises tests carried out to identify and quantify minute amounts of DNA from host cells found in biopharmaceutical products.

Key Statistics:

• Market Size (2025): USD 312.62 Million
• Market Size (2034): USD 519.69 Million
• CAGR (2026-2034): 5.9%
• Dominating Region: North America

Report Highlights:

• Rising biologics production is increasing demand for residual DNA testing.
• Growth in vaccine manufacturing is supporting DNA contamination analysis.
• CRO services segment is projected to grow at the fastest CAGR of 6.5% during the forecast period, due to rising outsourcing of analytical testing activities.
• NGS segment is expected to grow with the highest CAGR of 6.4% over the forecast period, owing to the rising requirement for next generation sequencing technology for sensitive detection of DNA.
• Kits accounted for substantial market share of 15.5% in 2025, owing to its ease of use and regulatory compliance.
• North America residual DNA testing industry held 43.72% revenue market in 2025, driven by its advanced infrastructure for biopharmaceuticals.
• US held approximately 80% of revenue share within North America region due to strong biopharmaceutical infrastructure.
• Asia Pacific residual DNA testing industry is projected to grow at 6.5% CAGR during the forecast period, driven by increasing government support and growth in CDMOs.
• Key companies include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Danaher Corporation, Bio-Rad Laboratories Inc., and others.

What’s Included in Residual DNA Testing Report?

The report presents a detailed overview of the market for residual DNA testing based on product & service, technology, sample type, application, and end user. It includes regional analysis, testing workflow assessment, value chain analysis, and competitive landscape.

What are Driving Factors and Emerging Trends of Residual DNA Testing Market?

As per our analysis, the market is increasing due to rising biologics production and expansion of vaccine manufacturing. The major factors that are responsible for the growth of the residual DNA testing market are:

• Rising Biologics Production: Increasing biologics manufacturing is driving demand for residual DNA testing for product purity. India’s National Biopharma Mission targets a USD 100 Million biotech industry and 5% global pharma share by 2025.
• Vaccine Production Growth: Growing demands for vaccine production are necessitating the need to test for DNA contamination. The global production of vaccines increased to 14.5 Million doses with a market worth of 35 Million dollars in 2024-2025.
• Technology Advancements: Use of digital technology and AI-driven technologies is enhancing the efficiency of testing.

All these aspects are in harmony with rising regulations on product safety and quality control within biopharmaceutical production processes.

Request a free sample copy or read the full market insights: Residual DNA Testing Market Report

Which Key Segments are Driving Residual DNA Testing Market?

By Product & Service Analysis

The kits segment captured the highest market share owing to user-friendliness and consistent testing processes.

By Technology Analysis

The PCR segment dominated the market owing to the wide acceptance of qPCR residual DNA testing.

By Sample Type Analysis

The in-process segment dominated the market owing to the growing importance of real-time testing during manufacturing processes.

By Application Analysis

Biologics segment dominated the market due to high production of monoclonal antibodies and recombinant proteins.

By End User Analysis

Biotech segment dominated the market due to strong focus on advanced therapy development and quality control.

Which is Dominating Region in Residual DNA Testing Market?

North America: North America emerged as a dominant region in 2025 owing to its robust regulatory environment and highly developed biopharmaceutical industry infrastructure. In April 2025, LabCorp introduced residual disease and liquid biopsy tests for cancer diagnosis and monitoring.

Asia Pacific: The growth rate for Asia Pacific is anticipated to be the fastest owing to biologics and vaccine production capabilities. In May 2025, Gene Solutions collaborated with NEWCL to provide next-generation sequencing (NGS) genetic testing solutions in Taiwan.

Where is Residual DNA Testing Market Headed?

According to analysis, the market is moving toward steady expansion supported by advanced DNA detection technologies, automation, and growth in biologics and gene therapy pipelines.

What Residual DNA Testing Market Report Reveals?

• What is the global market size, growth trend, and CAGR for residual DNA testing through 2034?
• What are the factors driving the market growth?
• Who are the top companies, and what is their relative position in terms of competitive positioning?
• How are companies adopting AI-based analytics to improve residual DNA testing accuracy?
• How is growth in gene therapy shaping demand for high-sensitivity DNA detection technologies?
• What are the trends in the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
• Where do new opportunities arise in the residual DNA testing market?

Who are Major Residual DNA Testing Market Contributors?

According to our study, a few firms are leading in the global market. The following are some of the major market contributors:

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Charles River Laboratories International Inc.
• Danaher Corporation
• Eurofins Scientific SE
• Lonza Group AG
• Merck KGaA
• PerkinElmer Inc.
• QIAGEN N.V.
• Sartorius AG
• SGS SA
• Thermo Fisher Scientific Inc.

Market Segments Covered

By Product & Service Outlook (Revenue, USD Million, 2021-2034)

• Kits
• Reagents
• Instruments
• CRO Services

By Technology Outlook (Revenue, USD Million, 2021-2034)

• PCR
• NGS
• ELISA

By Sample Type Outlook (Revenue, USD Million, 2021-2034)

• Raw Materials
• In-Process
• Final Product
• Fill-Finish

By Application Outlook (Revenue, USD Million, 2021-2034)

• Biologics
• Vaccines
• Gene Therapy
• Biosimilars

By End User Outlook (Revenue, USD Million, 2021-2034)

• Pharma
• Biotech
• CROs
• CDMOs

By Regional Outlook (Revenue, USD Million, 2021-2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Rest of Middle East & Africa